Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25372775 | 1.00 | FFAR3 (0.39) | FFAR3ARG1ARG2CYP2C19PARP1 | |
| SCHEMBL14488376 | 1.00 | FFAR3 (0.39) | FFAR3ARG1ARG2CYP2C19PARP1 | |
| Hydrochloric Acid SCHEMBL16584573 | 0.98 | FFAR3 (0.37) | FFAR3ARG1ARG2CYP2C19 | |
| Hydrochloric Acid SCHEMBL5968897 | 0.98 | FFAR3 (0.37) | FFAR3ARG1ARG2CYP2C19 | |
| Hydrochloric Acid SCHEMBL927105 | 0.98 | FFAR3 (0.37) | FFAR3ARG1ARG2CYP2C19 | |
| SCHEMBL697443 | 0.93 | — | — | |
| SCHEMBL573927 | 0.93 | — | — | |
| SCHEMBL3325667 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL17393208 | 0.91 | FFAR3 (0.39) | FFAR3ARG1ARG2PARP1 | |
| Bromide SCHEMBL14659502 | 0.91 | FFAR3 (0.39) | FFAR3ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573934-B2 | Methods and compositions for the synthesis of multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | claimed |
| US-20150148543-A1 | Methods and Compositions for the Synthesis of Multimerizing Agents | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-28 | — | — | US | claimed |
| US-9024028-B2 | Methods and compositions for the synthesis of multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | claimed |
| US-20140171649-A1 | Methods and Compositions for the Synthesis of Multimerizing Agents | ARIAD PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | claimed |
| WO-2012103279-A2 | METHODS AND COMPOSITIONS FOR THE SYNTHESIS OF MULTIMERIZING AGENTS | ARIAD PHARMACEUTICALS, INCORPORATED (US) | 2012-08-02 | — | — | WO | claimed |
| EP-1773877-B1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL MYERS SQUIBB CO (US) | 2010-03-17 | — | — | EP | claimed |
| CN-101400699-A | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2009-04-01 | — | — | CN | claimed |
| EP-1976873-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Brystol-Myers Squibb Company (US) | 2008-10-08 | — | — | EP | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| CN-101010339-A | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL MYERS SQUIBB CO (US) | 2007-08-01 | — | — | CN | claimed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | claimed |
| EP-1773877-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | claimed |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | claimed |
| WO-2006014287-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | claimed |
| EP-0378318-A1 | Process for synthesis of FK-506 and tricarbonyl intermediates | MERCK & CO. INC. (US) | 1990-07-18 | — | — | EP | claimed |
| EP-4151622-B1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN DRUG | SICHUAN ACAD OF MEDICAL SCIENCES SICHUAN PROVINCIAL PEOPLES HOSPITAL (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-20240168029-A1 | APPLICATION OF COMPOSITION IN PREPARATION OF DRUG FOR DIAGNOSING INFANTILE HEMANGIOMA AND/OR MONITORING PROGRESS AND PROGNOSIS THEREOF, AND KIT AND DRUG | JIANG CHENGHONG (CN) | 2024-05-23 | — | — | US | disclosed |
| US-5164525-A | SYNTHETIC PROCESS FOR FK-506 TYPE MACROLIDE INTERMEDIATES | MERCK & CO., INC. (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0405994-A2 | Synthetic process for FK-506 type macrolide intermediates | MERCK & CO. INC. (US) | 1991-01-02 | — | — | EP | disclosed |
| EP-0378318-A1 | Process for synthesis of FK-506 and tricarbonyl intermediates | MERCK & CO. INC. (US) | 1990-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | FFAR3 95/4885ARG1 829/4885ARG2 798/4885 |
| US-20140171649-A1 | Methods and Compositions for the Synthesis of Multimerizing Agents | PIP5K1C, PIP4K2C, IPMK | FFAR3 2153/4885ARG1 2677/4885ARG2 3452/4885 |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | GLP1R, GIPR, IAPP | FFAR3 101/4885ARG1 694/4885ARG2 760/4885 |
| US-20150148543-A1 | Methods and Compositions for the Synthesis of Multimerizing Agents | PARG, POLI, MCM6 | FFAR3 4869/4885ARG1 3961/4885ARG2 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.